{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:05:04Z","timestamp":1776690304976,"version":"3.51.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["CRC-2020-00067"],"award-info":[{"award-number":["CRC-2020-00067"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FRN-167269"],"award-info":[{"award-number":["FRN-167269"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001805","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["John R. Evans Leaders Funds #34272"],"award-info":[{"award-number":["John R. Evans Leaders Funds #34272"]}],"id":[{"id":"10.13039\/501100001805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15193-7","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:52:14Z","timestamp":1763545934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Ariane","family":"Lapointe-Belleau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mich\u00e8le","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyne","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Descarreaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Caron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Beaudoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwini","family":"Uchil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Simonyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cylia","family":"Dahmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Joly-Beauparlant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"G\u00e9linas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Droit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Marcoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Castonguay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9ric","family":"L\u00e9vesque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1113-1212","authenticated-orcid":false,"given":"Chantal","family":"Guillemette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"26","key":"15193_CR1","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/JCO.23.00433","volume":"41","author":"C Dai","year":"2023","unstructured":"Dai C, Dehm SM, Sharifi N. Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. 2023;41(26):4267\u201378.","journal-title":"J Clin Oncol"},{"issue":"21","key":"15193_CR2","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"issue":"13","key":"15193_CR3","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397.","journal-title":"N Engl J Med"},{"issue":"2","key":"15193_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152\u201360.","journal-title":"Lancet Oncol"},{"issue":"5","key":"15193_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333.","journal-title":"N Engl J Med"},{"issue":"12","key":"15193_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701\u201311.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"15193_CR7","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447\u201354.","journal-title":"Cancer Res"},{"issue":"7","key":"15193_CR8","doi-asserted-by":"publisher","first-page":"e0159867","DOI":"10.1371\/journal.pone.0159867","volume":"11","author":"E Pretorius","year":"2016","unstructured":"Pretorius E, Africander DJ, Vlok M, Perkins MS, Quanson J, Storbeck KH. 11-ketotestosterone and 11-ketodihydrotestosterone in castration resistant prostate cancer: potent androgens which can no longer be ignored. PLoS ONE. 2016;11(7):e0159867.","journal-title":"PLoS ONE"},{"issue":"5","key":"15193_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41574-020-0336-x","volume":"16","author":"AF Turcu","year":"2020","unstructured":"Turcu AF, Rege J, Auchus RJ, Rainey WE. 11-oxygenated androgens in health and disease. Nat Rev Endocrinol. 2020;16(5):284\u201396.","journal-title":"Nat Rev Endocrinol"},{"key":"15193_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jsbmb.2017.07.034","volume":"174","author":"L Barnard","year":"2017","unstructured":"Barnard L, Gent R, van Rooyen D, Swart AC. Adrenal C11-oxy C21 steroids contribute to the C11-oxy C19 steroid pool via the backdoor pathway in the biosynthesis and metabolism of 21-deoxycortisol and 21-deoxycortisone. J Steroid Biochem Mol Biol. 2017;174:86\u201395.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"15193_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.mce.2017.09.026","volume":"461","author":"T du Toit","year":"2018","unstructured":"du Toit T, Swart AC. Inefficient UGT-conjugation of adrenal 11beta-hydroxyandrostenedione metabolites highlights C11-oxy C(19) steroids as the predominant androgens in prostate cancer. Mol Cell Endocrinol. 2018;461:265\u201376.","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"15193_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/MED.0000000000000334","volume":"24","author":"AF Turcu","year":"2017","unstructured":"Turcu AF, Auchus RJ. Clinical significance of 11-oxygenated androgens. Curr Opin Endocrinol Diabetes Obes. 2017;24(3):252\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"15193_CR13","doi-asserted-by":"crossref","unstructured":"Snaterse G, van Dessel LF, van Riet J, Taylor AE, van der Vlugt-Daane M, Hamberg P, et al. 11-ketotestosterone is the predominant active androgen in prostate cancer patients after castration. JCI Insight. 2021;6(11):e148507.","DOI":"10.1172\/jci.insight.148507"},{"issue":"3","key":"15193_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/JU.0000000000004333","volume":"213","author":"C Dahmani","year":"2025","unstructured":"Dahmani C, Caron P, Simonyan D, Lacombe L, Aprikian A, Saad F, et al. High 11-ketotestosterone linked to shorter time to castration resistance in recurrent nonmetastatic prostate cancer. J Urol. 2025;213(3):283\u201394.","journal-title":"J Urol"},{"issue":"1","key":"15193_CR15","doi-asserted-by":"publisher","first-page":"e220072","DOI":"10.1530\/EO-22-0072","volume":"3","author":"G Snaterse","year":"2023","unstructured":"Snaterse G, Hofland J, Lapauw B. The role of 11-oxygenated androgens in prostate cancer. Endocrine Oncology. 2023;3(1):e220072.","journal-title":"Endocrine Oncology"},{"key":"15193_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jsbmb.2018.06.013","volume":"183","author":"M Barnard","year":"2018","unstructured":"Barnard M, Quanson JL, Mostaghel E, Pretorius E, Snoep JL, Storbeck KH. 11-oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): implications for castration resistant prostate cancer. J Steroid Biochem Mol Biol. 2018;183:192\u2013201.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"15193_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41391-022-00491-z","volume":"26","author":"G Snaterse","year":"2023","unstructured":"Snaterse G, Mies R, van Weerden WM, French PJ, Jonker JW, Houtsmuller AB, et al. Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. Prostate Cancer Prostatic Dis. 2023;26(2):293\u2013301.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"15193_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.mce.2016.08.014","volume":"441","author":"E Pretorius","year":"2017","unstructured":"Pretorius E, Arlt W, Storbeck KH. A new dawn for androgens: novel lessons from 11-oxygenated C19 steroids. Mol Cell Endocrinol. 2017;441:76\u201385.","journal-title":"Mol Cell Endocrinol"},{"key":"15193_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jsbmb.2019.02.013","volume":"189","author":"R Gent","year":"2019","unstructured":"Gent R, du Toit T, Bloem LM, Swart AC. The 11beta-hydroxysteroid dehydrogenase isoforms: pivotal catalytic activities yield potent C11-oxy C(19) steroids with 11betaHSD2 favouring 11-ketotestosterone, 11-ketoandrostenedione and 11-ketoprogesterone biosynthesis. J Steroid Biochem Mol Biol. 2019;189:116\u201326.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1\u20132","key":"15193_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.mce.2013.07.006","volume":"377","author":"KH Storbeck","year":"2013","unstructured":"Storbeck KH, Bloem LM, Africander D, Schloms L, Swart P, Swart AC. 11beta-hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer? Mol Cell Endocrinol. 2013;377(1\u20132):135\u201346.","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"15193_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/JU.0000000000003049","volume":"209","author":"C Dahmani","year":"2023","unstructured":"Dahmani C, Caron P, Simonyan D, Lacombe L, Aprikian A, Saad F, et al. Preoperative circulating 11-oxygenated androgens are associated with metastasis-free survival in localized prostate cancer. J Urol. 2023;209(2):337\u201346.","journal-title":"J Urol"},{"issue":"3","key":"15193_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.clgc.2018.01.005","volume":"16","author":"M Claps","year":"2018","unstructured":"Claps M, Petrelli F, Caffo O, Amoroso V, Roca E, Mosca A, Maines F, Barni S, Berruti A. Testosterone levels and prostate cancer prognosis: systematic review and meta-analysis. Clin Genitourin Cancer. 2018;16(3):165-175 e162.","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"15193_CR23","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s10147-020-01747-1","volume":"25","author":"N Miura","year":"2020","unstructured":"Miura N, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, Abufaraj M, et al. Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. Int J Clin Oncol. 2020;25(11):1881\u201391.","journal-title":"Int J Clin Oncol"},{"key":"15193_CR24","doi-asserted-by":"publisher","first-page":"462228","DOI":"10.1016\/j.chroma.2021.462228","volume":"1650","author":"P Caron","year":"2021","unstructured":"Caron P, Turcotte V, Guillemette C. A quantitative analysis of total and free 11-oxygenated androgens and its application to human serum and plasma specimens using liquid-chromatography tandem mass spectrometry. J Chromatogr A. 2021;1650:462228.","journal-title":"J Chromatogr A"},{"key":"15193_CR25","doi-asserted-by":"publisher","first-page":"104372","DOI":"10.1016\/j.dib.2019.104372","volume":"25","author":"RTK Poluri","year":"2019","unstructured":"Poluri RTK, Beauparlant CJ, Droit A, Audet-Walsh E. RNA sequencing data of human prostate cancer cells treated with androgens. Data Brief. 2019;25:104372.","journal-title":"Data Brief"},{"issue":"1","key":"15193_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.mce.2010.08.008","volume":"331","author":"H Makkonen","year":"2011","unstructured":"Makkonen H, Kauhanen M, Jaaskelainen T, Palvimo JJ. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. Mol Cell Endocrinol. 2011;331(1):57\u201365.","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"15193_CR27","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1111\/cts.13372","volume":"15","author":"S Derderian","year":"2022","unstructured":"Derderian S, Vesval Q, Wissing MD, Hamel L, Cote N, Vanhuyse M, et al. Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer. Clin Transl Sci. 2022;15(11):2597\u2013612.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"15193_CR28","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1158\/0008-5472.CAN-20-1417","volume":"81","author":"A Alpsoy","year":"2021","unstructured":"Alpsoy A, Utturkar SM, Carter BC, Dhiman A, Torregrosa-Allen SE, Currie MP, et al. BRD9 is a critical regulator of Androgen Receptor signaling and prostate cancer progression. Cancer Res. 2021;81(4):820\u201333.","journal-title":"Cancer Res"},{"key":"15193_CR29","doi-asserted-by":"crossref","unstructured":"Cordova RA, Misra J, Amin PH, Klunk AJ, Damayanti NP, Carlson KR, Elmendorf AJ, Kim HG, Mirek ET, Elzey BD et al. GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis. Elife. 2022;11:e81083.","DOI":"10.7554\/eLife.81083"},{"key":"15193_CR30","doi-asserted-by":"publisher","first-page":"101578","DOI":"10.1016\/j.tranon.2022.101578","volume":"27","author":"Z Ye","year":"2023","unstructured":"Ye Z, Xia Y, Li L, Li B, Chen W, Han S, et al. Effect of transmembrane protein 100 on prostate cancer progression by regulating SCNN1D through the FAK\/PI3K\/AKT pathway. Transl Oncol. 2023;27:101578.","journal-title":"Transl Oncol"},{"issue":"1","key":"15193_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41467-024-44686-5","volume":"15","author":"S Panja","year":"2024","unstructured":"Panja S, Truica MI, Yu CY, Saggurthi V, Craige MW, Whitehead K, et al. Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Nat Commun. 2024;15(1):352.","journal-title":"Nat Commun"},{"issue":"5","key":"15193_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/jclinpath-2016-203926","volume":"70","author":"HY Zhang","year":"2017","unstructured":"Zhang HY, Ma YD, Zhang Y, Cui J, Wang ZM. Elevated levels of autophagy-related marker ULK1 and mitochondrion-associated autophagy inhibitor LRPPRC are associated with biochemical progression and overall survival after androgen deprivation therapy in patients with metastatic prostate cancer. J Clin Pathol. 2017;70(5):383\u20139.","journal-title":"J Clin Pathol"},{"issue":"22","key":"15193_CR33","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1200\/JCO.2012.45.4595","volume":"31","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol. 2013;31(22):2791\u20138.","journal-title":"J Clin Oncol"},{"key":"15193_CR34","doi-asserted-by":"crossref","unstructured":"Wang T, Ahmad S, Cruz-Lebron A, Ernst SE, Olivos Caicedo KY, Jeong Y, et al. An expanded metabolic pathway for androgen production by commensal bacteria. Nat Microbiol. 2025;10(5):1084\u201398.","DOI":"10.1038\/s41564-025-01979-9"},{"issue":"3","key":"15193_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/pros.10290","volume":"57","author":"A van Bokhoven","year":"2003","unstructured":"van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003;57(3):205\u201325.","journal-title":"Prostate"},{"issue":"6","key":"15193_CR36","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309\u201322.","journal-title":"Cell"},{"issue":"6","key":"15193_CR37","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ccr.2009.11.006","volume":"16","author":"G Attard","year":"2009","unstructured":"Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell. 2009;16(6):458\u201362.","journal-title":"Cancer Cell"},{"key":"15193_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jsbmb.2016.06.009","volume":"166","author":"T du Toit","year":"2017","unstructured":"du Toit T, Bloem LM, Quanson JL, Ehlers R, Serafin AM, Swart AC. Profiling adrenal 11beta-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC(2)-MS\/MS quantification of 11beta-hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone. J Steroid Biochem Mol Biol. 2017;166:54\u201367.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"8","key":"15193_CR39","doi-asserted-by":"publisher","first-page":"R146","DOI":"10.1530\/EC-17-0118","volume":"6","author":"E Jernberg","year":"2017","unstructured":"Jernberg E, Bergh A, Wikstrom P. Clinical relevance of androgen receptor alterations in prostate cancer. Endocr Connect. 2017;6(8):R146\u201361.","journal-title":"Endocr Connect"},{"issue":"4","key":"15193_CR40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1530\/EJE-19-0905","volume":"182","author":"C Wright","year":"2020","unstructured":"Wright C, O\u2019Day P, Alyamani M, Sharifi N, Auchus RJ. Abiraterone acetate treatment lowers 11-oxygenated androgens. Eur J Endocrinol. 2020;182(4):413\u201321.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"15193_CR41","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-22-0115","volume":"21","author":"M Karimaa","year":"2022","unstructured":"Karimaa M, Riikonen R, Kettunen H, Taavitsainen P, Ramela M, Chrusciel M, et al. First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis. Mol Cancer Ther. 2022;21(12):1765\u201376.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"15193_CR42","first-page":"EVIDoa2300171","volume":"3","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, Bernard-Tessier A, Roubaud G, Utriainen T, Barthelemy P, Flechon A, van der Voet J, Gravis G, Ratta R, Jones R, et al. Targeted inhibition of CYP11A1 in castration-resistant prostate cancer. NEJM Evid. 2024;3(1):EVIDoa2300171.","journal-title":"NEJM Evid"},{"issue":"1","key":"15193_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juarez Soto A, Merseburger AS, Ozguroglu M, Uemura H, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324.","journal-title":"N Engl J Med."},{"issue":"15","key":"15193_CR44","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with Enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616\u201322.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15193-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15193-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15193-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:03:06Z","timestamp":1763550186000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15193-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15193"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15193-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received approval from the Ethical Research Committee of the CHU de Qu\u00e9bec \u2013 Universit\u00e9 Laval (#2018\u20134125) and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1786"}}